Statins and Exercise Training Response in Heart Failure Patients: Insights From HF-ACTION

Jacob P. Kelly, Allison Dunning, Phillip J. Schulte, Mona Fiuzat, Eric S. Leifer, Jerome L. Fleg, Lawton S. Cooper, Steven J. Keteyian, Dalane W. Kitzman, Ileana L. Pina, William E. Kraus, David J. Whellan, Christopher M. O'Connor, Robert J. Mentz

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objectives The aim of this study was to assess for a treatment interaction between statin use and exercise training (ET) response. Background Recent data suggest that statins may attenuate ET response, but limited data exist in patients with heart failure (HF). Methods HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) was a randomized trial of 2,331 patients with chronic HF with ejection fraction ≤35% who were randomized to usual care with or without ET. We evaluated whether there was a treatment interaction between statins and ET response for the change in quality of life and aerobic capacity (peak oxygen consumption and 6-min walk distance) from baseline to 3 months. We also assessed for a treatment interaction among atorvastatin, simvastatin, and pravastatin and change in these endpoints with ET. Multiple linear regression analyses were performed for each endpoint, adjusting for baseline covariates. Results Of 2,331 patients in the HF-ACTION trial, 1,353 (58%) were prescribed statins at baseline. Patients treated with statins were more likely to be older men with ischemic HF etiology but had similar use of renin angiotensin system blockers and beta-blockers. There was no evidence of a treatment interaction between statin use and ET on changes in quality of life or exercise capacity, nor was there evidence of differential association between statin type and ET response for these endpoints (all p values >0.05). Conclusions In a large chronic HF cohort, there was no evidence of a treatment interaction between statin use and short-term change in aerobic capacity and quality of life with ET. These findings contrast with recent reports of an attenuation in ET response with statins in a different population, highlighting the need for future prospective studies. (Exercise Training Program to Improve Clinical Outcomes in Individuals With Congestive Heart Failure; NCT00047437)

Original languageEnglish (US)
Pages (from-to)617-624
Number of pages8
JournalJACC: Heart Failure
Volume4
Issue number8
DOIs
StatePublished - Aug 1 2016

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Heart Failure
Exercise
Quality of Life
Therapeutics
Pravastatin
Simvastatin
Renin-Angiotensin System
Oxygen Consumption
Linear Models

Keywords

  • chronic heart failure
  • exercise training
  • heart failure with reduced ejection fraction
  • statins

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Kelly, J. P., Dunning, A., Schulte, P. J., Fiuzat, M., Leifer, E. S., Fleg, J. L., ... Mentz, R. J. (2016). Statins and Exercise Training Response in Heart Failure Patients: Insights From HF-ACTION. JACC: Heart Failure, 4(8), 617-624. https://doi.org/10.1016/j.jchf.2016.05.006

Statins and Exercise Training Response in Heart Failure Patients : Insights From HF-ACTION. / Kelly, Jacob P.; Dunning, Allison; Schulte, Phillip J.; Fiuzat, Mona; Leifer, Eric S.; Fleg, Jerome L.; Cooper, Lawton S.; Keteyian, Steven J.; Kitzman, Dalane W.; Pina, Ileana L.; Kraus, William E.; Whellan, David J.; O'Connor, Christopher M.; Mentz, Robert J.

In: JACC: Heart Failure, Vol. 4, No. 8, 01.08.2016, p. 617-624.

Research output: Contribution to journalArticle

Kelly, JP, Dunning, A, Schulte, PJ, Fiuzat, M, Leifer, ES, Fleg, JL, Cooper, LS, Keteyian, SJ, Kitzman, DW, Pina, IL, Kraus, WE, Whellan, DJ, O'Connor, CM & Mentz, RJ 2016, 'Statins and Exercise Training Response in Heart Failure Patients: Insights From HF-ACTION', JACC: Heart Failure, vol. 4, no. 8, pp. 617-624. https://doi.org/10.1016/j.jchf.2016.05.006
Kelly, Jacob P. ; Dunning, Allison ; Schulte, Phillip J. ; Fiuzat, Mona ; Leifer, Eric S. ; Fleg, Jerome L. ; Cooper, Lawton S. ; Keteyian, Steven J. ; Kitzman, Dalane W. ; Pina, Ileana L. ; Kraus, William E. ; Whellan, David J. ; O'Connor, Christopher M. ; Mentz, Robert J. / Statins and Exercise Training Response in Heart Failure Patients : Insights From HF-ACTION. In: JACC: Heart Failure. 2016 ; Vol. 4, No. 8. pp. 617-624.
@article{33bb4222a1164da284de6b0b1b20b401,
title = "Statins and Exercise Training Response in Heart Failure Patients: Insights From HF-ACTION",
abstract = "Objectives The aim of this study was to assess for a treatment interaction between statin use and exercise training (ET) response. Background Recent data suggest that statins may attenuate ET response, but limited data exist in patients with heart failure (HF). Methods HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) was a randomized trial of 2,331 patients with chronic HF with ejection fraction ≤35{\%} who were randomized to usual care with or without ET. We evaluated whether there was a treatment interaction between statins and ET response for the change in quality of life and aerobic capacity (peak oxygen consumption and 6-min walk distance) from baseline to 3 months. We also assessed for a treatment interaction among atorvastatin, simvastatin, and pravastatin and change in these endpoints with ET. Multiple linear regression analyses were performed for each endpoint, adjusting for baseline covariates. Results Of 2,331 patients in the HF-ACTION trial, 1,353 (58{\%}) were prescribed statins at baseline. Patients treated with statins were more likely to be older men with ischemic HF etiology but had similar use of renin angiotensin system blockers and beta-blockers. There was no evidence of a treatment interaction between statin use and ET on changes in quality of life or exercise capacity, nor was there evidence of differential association between statin type and ET response for these endpoints (all p values >0.05). Conclusions In a large chronic HF cohort, there was no evidence of a treatment interaction between statin use and short-term change in aerobic capacity and quality of life with ET. These findings contrast with recent reports of an attenuation in ET response with statins in a different population, highlighting the need for future prospective studies. (Exercise Training Program to Improve Clinical Outcomes in Individuals With Congestive Heart Failure; NCT00047437)",
keywords = "chronic heart failure, exercise training, heart failure with reduced ejection fraction, statins",
author = "Kelly, {Jacob P.} and Allison Dunning and Schulte, {Phillip J.} and Mona Fiuzat and Leifer, {Eric S.} and Fleg, {Jerome L.} and Cooper, {Lawton S.} and Keteyian, {Steven J.} and Kitzman, {Dalane W.} and Pina, {Ileana L.} and Kraus, {William E.} and Whellan, {David J.} and O'Connor, {Christopher M.} and Mentz, {Robert J.}",
year = "2016",
month = "8",
day = "1",
doi = "10.1016/j.jchf.2016.05.006",
language = "English (US)",
volume = "4",
pages = "617--624",
journal = "JACC: Heart Failure",
issn = "2213-1779",
publisher = "Elsevier BV",
number = "8",

}

TY - JOUR

T1 - Statins and Exercise Training Response in Heart Failure Patients

T2 - Insights From HF-ACTION

AU - Kelly, Jacob P.

AU - Dunning, Allison

AU - Schulte, Phillip J.

AU - Fiuzat, Mona

AU - Leifer, Eric S.

AU - Fleg, Jerome L.

AU - Cooper, Lawton S.

AU - Keteyian, Steven J.

AU - Kitzman, Dalane W.

AU - Pina, Ileana L.

AU - Kraus, William E.

AU - Whellan, David J.

AU - O'Connor, Christopher M.

AU - Mentz, Robert J.

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Objectives The aim of this study was to assess for a treatment interaction between statin use and exercise training (ET) response. Background Recent data suggest that statins may attenuate ET response, but limited data exist in patients with heart failure (HF). Methods HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) was a randomized trial of 2,331 patients with chronic HF with ejection fraction ≤35% who were randomized to usual care with or without ET. We evaluated whether there was a treatment interaction between statins and ET response for the change in quality of life and aerobic capacity (peak oxygen consumption and 6-min walk distance) from baseline to 3 months. We also assessed for a treatment interaction among atorvastatin, simvastatin, and pravastatin and change in these endpoints with ET. Multiple linear regression analyses were performed for each endpoint, adjusting for baseline covariates. Results Of 2,331 patients in the HF-ACTION trial, 1,353 (58%) were prescribed statins at baseline. Patients treated with statins were more likely to be older men with ischemic HF etiology but had similar use of renin angiotensin system blockers and beta-blockers. There was no evidence of a treatment interaction between statin use and ET on changes in quality of life or exercise capacity, nor was there evidence of differential association between statin type and ET response for these endpoints (all p values >0.05). Conclusions In a large chronic HF cohort, there was no evidence of a treatment interaction between statin use and short-term change in aerobic capacity and quality of life with ET. These findings contrast with recent reports of an attenuation in ET response with statins in a different population, highlighting the need for future prospective studies. (Exercise Training Program to Improve Clinical Outcomes in Individuals With Congestive Heart Failure; NCT00047437)

AB - Objectives The aim of this study was to assess for a treatment interaction between statin use and exercise training (ET) response. Background Recent data suggest that statins may attenuate ET response, but limited data exist in patients with heart failure (HF). Methods HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) was a randomized trial of 2,331 patients with chronic HF with ejection fraction ≤35% who were randomized to usual care with or without ET. We evaluated whether there was a treatment interaction between statins and ET response for the change in quality of life and aerobic capacity (peak oxygen consumption and 6-min walk distance) from baseline to 3 months. We also assessed for a treatment interaction among atorvastatin, simvastatin, and pravastatin and change in these endpoints with ET. Multiple linear regression analyses were performed for each endpoint, adjusting for baseline covariates. Results Of 2,331 patients in the HF-ACTION trial, 1,353 (58%) were prescribed statins at baseline. Patients treated with statins were more likely to be older men with ischemic HF etiology but had similar use of renin angiotensin system blockers and beta-blockers. There was no evidence of a treatment interaction between statin use and ET on changes in quality of life or exercise capacity, nor was there evidence of differential association between statin type and ET response for these endpoints (all p values >0.05). Conclusions In a large chronic HF cohort, there was no evidence of a treatment interaction between statin use and short-term change in aerobic capacity and quality of life with ET. These findings contrast with recent reports of an attenuation in ET response with statins in a different population, highlighting the need for future prospective studies. (Exercise Training Program to Improve Clinical Outcomes in Individuals With Congestive Heart Failure; NCT00047437)

KW - chronic heart failure

KW - exercise training

KW - heart failure with reduced ejection fraction

KW - statins

UR - http://www.scopus.com/inward/record.url?scp=84992349010&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992349010&partnerID=8YFLogxK

U2 - 10.1016/j.jchf.2016.05.006

DO - 10.1016/j.jchf.2016.05.006

M3 - Article

C2 - 27395348

AN - SCOPUS:84992349010

VL - 4

SP - 617

EP - 624

JO - JACC: Heart Failure

JF - JACC: Heart Failure

SN - 2213-1779

IS - 8

ER -